Analysts Expect Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Post Earnings of -$0.56 Per Share

Equities research analysts forecast that Seres Therapeutics, Inc. (NASDAQ:MCRBGet Rating) will report earnings of ($0.56) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Seres Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.61) and the highest estimate coming in at ($0.48). Seres Therapeutics reported earnings per share of ($0.39) during the same quarter last year, which would indicate a negative year-over-year growth rate of 43.6%. The firm is expected to issue its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Seres Therapeutics will report full year earnings of ($2.05) per share for the current financial year, with EPS estimates ranging from ($2.59) to ($1.47). For the next financial year, analysts forecast that the firm will report earnings of ($1.16) per share, with EPS estimates ranging from ($2.86) to $0.29. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last issued its quarterly earnings results on Tuesday, March 1st. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). The firm had revenue of $7.22 million for the quarter, compared to analyst estimates of $19.48 million. Seres Therapeutics had a negative return on equity of 47.52% and a negative net margin of 45.25%. During the same quarter last year, the firm earned ($0.18) earnings per share.

Several research firms have issued reports on MCRB. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 3rd. StockNews.com assumed coverage on shares of Seres Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, Seres Therapeutics currently has an average rating of “Hold” and a consensus target price of $20.83.

Large investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its position in shares of Seres Therapeutics by 3.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 67,000 shares of the biotechnology company’s stock worth $577,000 after purchasing an additional 2,000 shares during the last quarter. California State Teachers Retirement System increased its position in Seres Therapeutics by 2.1% during the fourth quarter. California State Teachers Retirement System now owns 96,007 shares of the biotechnology company’s stock worth $800,000 after buying an additional 2,007 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Seres Therapeutics by 90.3% in the second quarter. Royal Bank of Canada now owns 4,765 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 2,261 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of Seres Therapeutics by 23.0% in the fourth quarter. Teacher Retirement System of Texas now owns 13,562 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 2,536 shares in the last quarter. Finally, Credit Suisse AG boosted its stake in shares of Seres Therapeutics by 8.5% during the third quarter. Credit Suisse AG now owns 46,454 shares of the biotechnology company’s stock valued at $323,000 after acquiring an additional 3,644 shares during the last quarter. 80.70% of the stock is owned by institutional investors and hedge funds.

MCRB opened at $4.73 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 3.69 and a quick ratio of 3.69. Seres Therapeutics has a 12 month low of $4.61 and a 12 month high of $25.06. The stock has a market capitalization of $435.23 million, a P/E ratio of -6.31 and a beta of 3.36. The business has a 50 day simple moving average of $6.80 and a 200-day simple moving average of $7.67.

Seres Therapeutics Company Profile (Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

See Also

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.